We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Implanted Device Reduces Sleep Apnea Episodes

By HospiMedica International staff writers
Posted on 29 Jan 2014
Print article
Image: The Inspire UAS device (Photo courtesy of Inspire Medical Systems).
Image: The Inspire UAS device (Photo courtesy of Inspire Medical Systems).
Patients with obstructive sleep apnea (OSA) that used a new implanted device had an approximately 70% reduction in OSA severity, according to a new study.

Researchers at the University of Pittsburgh (Pitt, PA, USA), the University of Mannheim (Germany), and other institutions participating in the multicenter prospective stimulation therapy for apnea reduction (STAR) trial surgically implanted the device in 126 patients (83% men, mean age 54.5 years, mean body-mass index (BMI) 28.4) with OSA who had difficulty either accepting or adhering to continuous positive airway pressure (CPAP) therapy. The primary outcome measures were apnea-hypopnea index (AHI) and oxygen desaturation index (ODI).

For the study, the researchers used the Inspire upper airway stimulation (UAS) device, which was implanted in three areas: a stimulation electrode was placed on the hypoglossal nerve, which provides innervation to the muscles of the tongue; a sensing lead placed between rib muscles to detect breathing effort; and a neurostimulator implanted in the upper right chest, just below the clavicle bone. The device is designed to sense breathing patterns and deliver mild stimulation to a patient’s airway muscles to keep the airway open during sleep. The patients used a controller to turn on the device at night just before sleep.

The results showed that median AHI score at 12 months decreased by 68%, and the ODI score decreased by 70%; secondary outcome measures showed a reduction in the effects of OSA and improved quality of life; 86% of patients were still using the device every night at the one year mark. The AHI score was significantly higher (indicating more severe apnea) among the 23 participants in the therapy-withdrawal group, with ODI results showing a similar pattern. The rate of procedure-related serious adverse events was less than 2%. The results of the study were published on January 9, 2014, in the New England Journal of Medicine (NEJM).

“Inspire UAS therapy differs from other traditional sleep apnea devices and surgical procedures in that it targets the muscle tone of the throat rather than just the anatomy,” said coauthor assistant professor Ryan Soose, MD, of the Penn department of otolaryngology. “Two thirds of patients using the Inspire UAS therapy device had successful control of their OSA although even more reported improvement in snoring, daytime sleepiness and quality of life measures.”
The Inspire UAS device is a product of Inspire Medical Systems (Maple Grove, MN, USA), and is European Community (CE) marked.

Related Links:

University of Pittsburgh
University of Mannheim
Inspire Medical Systems


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Heart-Lung Machine
HL 40

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.